Eva Chalas

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

The American College of Obstetricians and Gynecologists in 2020

Eva Chalas · Obstetrics and Gynecology · 2020 · 436 citations

Reproductive Sciences, Reproductive Health, Gynecology +22

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors

Alex I. Zaika, Neda Slade, Susan Erster et al. · The Journal of Experimental Medicine · 2002 · 317 citations · Full text

The management of pseudomyxoma peritonei

William J. Mann, John L. Wagner, John Chumas et al. · Cancer · 1990 · 116 citations · Full text

Surgical Oncology, Medicine, Surgical Pathology +10